Use of integrase-minus lentiviral vector for transient expression

Cell Journal

Volumn 14, Issue 2, 2012, Pages 76-81

  Farazmandfar, Touraj ^a,b,c   Shahreza, Hossein Khanahmad ^d   Haghshenas, Mohammad Reza ^b   Janbabai, Ghasem ^b,c   Azadeh, Hossein ^c   Samaei, Nader Mansour ^a  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Pasteur Research and Production Complex   (Iran)

Author keywords

Integrase Minus; Lentiviral Vector; Transient Expression

Indexed keywords

ALANINE; ASPARTIC ACID; GLUTAMIC ACID; GREEN FLUORESCENT PROTEIN; INTEGRASE; INTEGRASE MINUS LENTIVIRAL VECTOR; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; FLUORESCENCE MICROSCOPY; GENE CASSETTE; GENE STRUCTURE; GENE TARGETING; GENETIC TRANSFECTION; MISSENSE MUTATION; NONHUMAN; SITE DIRECTED MUTAGENESIS; TRANSIENT EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

EID: 84865998895     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kulkosky J, Skalka AM. Molecular mechanism of retroviral DNA integration. Pharmacol Ther. 1994; 61(1-2): 185-203.
2. Hindmarsh P, Leis J. Retroviral DNA integration. Microbiol Mol Biol, Rev. 1999; 63(4): 836-843.
3. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259): 263-267.
4. Miyoshi H. Gene delivery to hematopoietic stem cells using lentiviral vectors. Methods Mol Biol. 2004; 246: 429-438.
5. Kafri T, Blömer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 1997; 17(3): 314-317.
6. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, Lowenstein PR. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther. 2005; 16(6): 741-751.
7. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72(11): 8463-8471.
8. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12): 9873-9880.
9. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 1993; 90(17): 8033-8037.
10. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003; 300(5626): 1749-1751.
11. Schröder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 Integration in the human genome favors active genes and local hotspots. Cell. 2002; 110(4): 521-529.
12. Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther. 2005; 12(4): 763-771.
13. Nightingale SJ, Hollis RP, Pepper KA, Petersen D, Yu XJ, Yang C, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther. 2006; 13(6): 1121-1132.
14. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A. 2006; 103(47): 17684-17689.
15. Leavitt AD, Robles G, Alesandro N, Varmus HE. Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol. 1996; 70(2): 721-728.
16. Gaur M, Leavitt AD. Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not elimi nate provirus formation. J Virol. 1998; 72(6): 4678-4685.
17. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995; 69(1): 376-386.
18. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol. 1995; 69(5): 2729-2736.
19. Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006; 12(3): 348-353.